logo

IOBT

IO Biotech·NASDAQ
--
--(--)
--
--(--)
4.19 / 10
Netural

IO Biotech's fundamental assessment is moderate (score 4.2/10). Strengths include a healthy interest-coverage ratio (15.48) and positive asset-to-market value, while weaknesses are highlighted by elevated days-sales-outstanding (72.55) and mixed revenue/profit multiples. Year-over-year revenue growth (92.66% operating revenue) is impressive but not yet reflected in profitability, leaving the balance-sheet and working-capital metrics as key watch-points. Overall, the company demonstrates growth potential but with constrained financial flexibility.

Fundamental(4.19)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.26
Score3/3
Weight18.76%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value78.47
Score2/3
Weight1.60%
1M Return1.11%
Days sales outstanding
Value72.55
Score1/3
Weight-2.06%
1M Return-1.57%
Profit-MV
Value0.46
Score2/3
Weight14.96%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight14.97%
1M Return8.45%
PB-ROE
Value-0.88
Score2/3
Weight18.65%
1M Return9.14%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.50%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value92.66
Score2/3
Weight0.62%
1M Return0.43%
Asset-MV
Value-0.50
Score2/3
Weight19.29%
1M Return10.15%
Cash-MV
Value-0.07
Score2/3
Weight14.71%
1M Return8.41%
Is IOBT undervalued or overvalued?
  • IOBT scores 4.19/10 on fundamentals and holds a Fair valuation at present. Backed by its -237.93% ROE, 0.00% net margin, -0.29 P/E ratio, 27.64 P/B ratio, and -3.88% earnings growth, these metrics solidify its Netural investment rating.